China’s CanSino Biologics Inc. has entered the “trial production phase” for its COVID-19 mRNA booster vaccine, the company said in a post on its social media account late Thursday.
The vaccine, known as CS-2034, targets the new Omicron variant of the virus, which has been responsible for the vast majority of infections since the country began to ease strict COVID restrictions last month. Had done it.
So far, China has relied on nine domestically developed COVID vaccines approved for use including inactivated vaccines, but none have been adapted to target the highly-transmissible Omicron variant and its offshoots that are currently in circulation. Huh.